Preclinical studies with platelet-activating factor antagonists in models of septic shock

Susan Quinn DeJoy, Arnold L. Oronsky, Michael M. Wick, S. S. Kerwar

Research output: Contribution to journalArticle

Abstract

Since the isolation and elucidation of the structure of platelet-activating factor (PAF) in the late 1970's, several preclinical studies have suggested that PAF is a key mediator of septic shock induced in animals by either endotoxin or by Gram-negative bacteria. A number of PAF antagonists have been sythesized that protect animals from the lethal effects of endotoxin. Some of these antagonists are in early stages of clinical development. The most advanced cadidate is BN 52021, a ginkgolide, that is in Phase II/III clinical trials in patients with septic shock. Preliminary results with BN 52021 indicate that it is efficacious and significantly reduces mortality associated with Gram-negative sepsis. Pivotal trials with BN 52021 aer ongoing. The present review summarizes the biological effects of PAF and the effect of PAF antagonists in animal models of septic shock. The interrelationship of PAF and tumor necrosis factor (another key mediator of septic shock) is also discussed.

Original languageEnglish (US)
Pages (from-to)175-186
Number of pages12
JournalInternational Journal of Antimicrobial Agents
Volume3
Issue number3
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

ginkgolide B
Platelet Activating Factor
Septic Shock
Endotoxins
Ginkgolides
Phase III Clinical Trials
Phase II Clinical Trials
Gram-Negative Bacteria
Sepsis
Animal Models
Tumor Necrosis Factor-alpha
Mortality

Keywords

  • Combination regimes
  • Platelet-activating factor
  • Platelet-activating factor antagonists
  • Septic shock
  • Therapies for spetic shock
  • Tumor necrosis factor

ASJC Scopus subject areas

  • Applied Microbiology and Biotechnology
  • Microbiology
  • Parasitology
  • Virology
  • Immunology and Allergy
  • Infectious Diseases

Cite this

Preclinical studies with platelet-activating factor antagonists in models of septic shock. / DeJoy, Susan Quinn; Oronsky, Arnold L.; Wick, Michael M.; Kerwar, S. S.

In: International Journal of Antimicrobial Agents, Vol. 3, No. 3, 1993, p. 175-186.

Research output: Contribution to journalArticle

DeJoy, Susan Quinn ; Oronsky, Arnold L. ; Wick, Michael M. ; Kerwar, S. S. / Preclinical studies with platelet-activating factor antagonists in models of septic shock. In: International Journal of Antimicrobial Agents. 1993 ; Vol. 3, No. 3. pp. 175-186.
@article{c00b0fc15136413eae7441a00773a9f0,
title = "Preclinical studies with platelet-activating factor antagonists in models of septic shock",
abstract = "Since the isolation and elucidation of the structure of platelet-activating factor (PAF) in the late 1970's, several preclinical studies have suggested that PAF is a key mediator of septic shock induced in animals by either endotoxin or by Gram-negative bacteria. A number of PAF antagonists have been sythesized that protect animals from the lethal effects of endotoxin. Some of these antagonists are in early stages of clinical development. The most advanced cadidate is BN 52021, a ginkgolide, that is in Phase II/III clinical trials in patients with septic shock. Preliminary results with BN 52021 indicate that it is efficacious and significantly reduces mortality associated with Gram-negative sepsis. Pivotal trials with BN 52021 aer ongoing. The present review summarizes the biological effects of PAF and the effect of PAF antagonists in animal models of septic shock. The interrelationship of PAF and tumor necrosis factor (another key mediator of septic shock) is also discussed.",
keywords = "Combination regimes, Platelet-activating factor, Platelet-activating factor antagonists, Septic shock, Therapies for spetic shock, Tumor necrosis factor",
author = "DeJoy, {Susan Quinn} and Oronsky, {Arnold L.} and Wick, {Michael M.} and Kerwar, {S. S.}",
year = "1993",
doi = "10.1016/0924-8579(93)90011-S",
language = "English (US)",
volume = "3",
pages = "175--186",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Preclinical studies with platelet-activating factor antagonists in models of septic shock

AU - DeJoy, Susan Quinn

AU - Oronsky, Arnold L.

AU - Wick, Michael M.

AU - Kerwar, S. S.

PY - 1993

Y1 - 1993

N2 - Since the isolation and elucidation of the structure of platelet-activating factor (PAF) in the late 1970's, several preclinical studies have suggested that PAF is a key mediator of septic shock induced in animals by either endotoxin or by Gram-negative bacteria. A number of PAF antagonists have been sythesized that protect animals from the lethal effects of endotoxin. Some of these antagonists are in early stages of clinical development. The most advanced cadidate is BN 52021, a ginkgolide, that is in Phase II/III clinical trials in patients with septic shock. Preliminary results with BN 52021 indicate that it is efficacious and significantly reduces mortality associated with Gram-negative sepsis. Pivotal trials with BN 52021 aer ongoing. The present review summarizes the biological effects of PAF and the effect of PAF antagonists in animal models of septic shock. The interrelationship of PAF and tumor necrosis factor (another key mediator of septic shock) is also discussed.

AB - Since the isolation and elucidation of the structure of platelet-activating factor (PAF) in the late 1970's, several preclinical studies have suggested that PAF is a key mediator of septic shock induced in animals by either endotoxin or by Gram-negative bacteria. A number of PAF antagonists have been sythesized that protect animals from the lethal effects of endotoxin. Some of these antagonists are in early stages of clinical development. The most advanced cadidate is BN 52021, a ginkgolide, that is in Phase II/III clinical trials in patients with septic shock. Preliminary results with BN 52021 indicate that it is efficacious and significantly reduces mortality associated with Gram-negative sepsis. Pivotal trials with BN 52021 aer ongoing. The present review summarizes the biological effects of PAF and the effect of PAF antagonists in animal models of septic shock. The interrelationship of PAF and tumor necrosis factor (another key mediator of septic shock) is also discussed.

KW - Combination regimes

KW - Platelet-activating factor

KW - Platelet-activating factor antagonists

KW - Septic shock

KW - Therapies for spetic shock

KW - Tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=0027745614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027745614&partnerID=8YFLogxK

U2 - 10.1016/0924-8579(93)90011-S

DO - 10.1016/0924-8579(93)90011-S

M3 - Article

VL - 3

SP - 175

EP - 186

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 3

ER -